Home Amgen, Allergan Biosimilar Avastin Hits In Trial
 

Keywords :   


Amgen, Allergan Biosimilar Avastin Hits In Trial

2015-09-24 17:07:51| Biotech - Topix.net

Amgen and Allergan, which started their collaboration back in 2011 when Allergan was a generic drug maker called Watson Pharmaceuticals, released few details but said the drug ABP 215 had shown clinical equivalence to Avastin as measured by tumor shrinkage, duration of response and progression-free survival. Launched in 2004, Avastin is drawing $7 billion for Roche as a treatment for a variety of different cancers, about 20% to 25% of it from lung cancer.

Tags: trial hits amgen allergan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.07Amazon at 30: What next for 'The Everything Company'?
05.07Atlantic Tropical Weather Outlook
05.07Could the 'flying piano' help transform air cargo?
05.07Eastern North Pacific Tropical Weather Outlook
04.07Hurricane Beryl Graphics
04.07Hurricane Beryl Forecast Discussion Number 25
04.07Hurricane Beryl Public Advisory Number 25
04.07Summary for Hurricane Beryl (AT2/AL022024)
More »